Clinical Trials

1,301 enrolled 16 charts

Melanoma

NCT04079712 2026-03-18

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

17 enrolled 12 charts

EndocrineNETThoracic

Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

378 enrolled 15 charts 1 FDA

Uveal Melanoma, Melanoma

NCT03071406 2026-03-11

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

50 enrolled 12 charts

Neoplasm Metastasis, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03999749 2026-03-09

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

71 enrolled 9 charts

Melanoma

NCT03036098 2026-03-06

CheckMate901

1,314 enrolled 23 charts 1 FDA

Genitourinary

Urothelial Cancer

NCT04396860 2026-03-05

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Phase 2/3 Completed

159 enrolled 17 charts

Sarcoma

Gliosarcoma

NCT04091750 2026-03-03

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

14 enrolled 9 charts

Melanoma

NCT03400332 2026-02-24

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Phase 1/2 Completed

281 enrolled 44 charts

Melanoma, Neoplasms

NCT05014776 2026-02-24

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

17 enrolled 8 charts

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT01274338 2026-02-18

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

1,673 enrolled 19 charts

Melanoma

NCT02224781 2026-02-18

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

267 enrolled 8 charts

970 enrolled 15 charts 1 FDA

Melanoma

NCT03143153 2026-02-17

CheckMate 648

Phase 3 Completed

Various Advanced Cancer

NCT03203473 2026-02-06

Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

85 enrolled 17 charts

Genitourinary

Kidney Neoplasms

NCT03789110 2026-02-06

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

30 enrolled 15 charts

Breast

Breast Neoplasms

NCT02919683 2026-01-28

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

30 enrolled 14 charts

Head & Neck

Head and Neck Neoplasms

NCT02648997 2026-01-26

An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

Phase 1/2 Active not recruiting

40 enrolled 14 charts

CNS

Meningioma

NCT03377023 2026-01-22

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

66 enrolled 17 charts

GastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung

NCT02408861 2026-01-21

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1 Terminated

79 enrolled 24 charts

Anus Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Sarcoma, Kaposi, HIV Infections

NCT03285321 2026-01-20

Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

105 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT03575793 2026-01-20

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Phase 1/2 Completed

39 enrolled 18 charts

Lung Neoplasms

NCT03873818 2026-01-09

Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

24 enrolled 13 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03425331 2026-01-08

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

Phase 2 Terminated

5 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT04326257 2026-01-08

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

505 enrolled 17 charts 1 FDA

20 enrolled 13 charts

Head & Neck

Diabetes Mellitus, Insulin-Dependent, 12, Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT02998528 2026-01-06

CheckMate 816

Phase 3 Completed

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03929029 2026-01-05

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

11 enrolled 11 charts

657 enrolled 57 charts 3 FDA

Melanoma

NCT01658878 2025-12-24

CheckMate040

Phase 1/2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT02985957 2025-12-22

CheckMate 650

351 enrolled 43 charts

Genitourinary

Prostatic Neoplasms

NCT01701674 2025-12-19

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

Phase NA Completed

13 enrolled 10 charts